Cost-effectiveness of Daclatasvir in Combination with Sofosbuvir for the Treatment of Subjects with Genotype 3 Chronic Hepatitis C Infection in the United States

被引：0
作者：
Thibault, Catherine St-Laurent [1 ]
Moorjaney, Divya [1 ]
Ganz, Michael [1 ]
Sill, Bruce E. [2 ]
Hede, Shalini [2 ]
Yuan, Yong [2 ]
Kalsekar, Anupama [2 ]
Gorsh, Boris [2 ]
机构：
[1] Evidera, Modeling & Simulat, St Laurent, PQ, Canada
[2] Bristol Myers Squibb Co, Plainsboro, NJ USA
来源：
HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1461
引用
收藏
页码：923A / 923A
页数：1
相关论文
共 50 条
[41]   LEDIPASVIR / SOFOSBUVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C: A COST-EFFECTIVENESS ANALYSIS ACROSS DIFFERENT GENOTYPE 1 CLINICAL SUBGROUPS [J].
Felix, J. ;
Almeida, J. ;
Ferreira, D. ;
Mota, M. ;
Afonso-Silva, M. ;
Silva, P. ;
Vandewalle, B. ;
Velosa, J. ;
Marinho, R. ;
Aldir, I ;
Carvalho, A. ;
Valente, C. ;
Macedo, G. ;
Sarmento e Castro, R. ;
Pedroto, I .
VALUE IN HEALTH, 2015, 18 (07) :A585-A585
[42]   COST-EFFECTIVENESS OF VELPATASVIR/SOFOSBUVIR FOR THE TREATMENT OF HEPATITIS C IN COLOMBIA [J].
Paternina-Caicedo, A. ;
Alvis-Guzman, N. ;
Alvis Zakzuk, J. ;
De La Hoz, F. .
VALUE IN HEALTH, 2023, 26 (06) :S103-S103
[43]   Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3 [J].
Belperio, Pamela S. ;
Shahoumian, Troy A. ;
Loomis, Timothy P. ;
Mole, Larry A. ;
Backus, Lisa I. .
JOURNAL OF HEPATOLOGY, 2019, 70 (01) :15-23
[44]   Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa [J].
Ilanca Fraser ;
Johanita Burger ;
Martie Lubbe ;
George Dranitsaris ;
Mark Sonderup ;
Tienie Stander .
PharmacoEconomics, 2016, 34 :403-417
[45]   Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection [J].
Younossi, Z. M. ;
Park, H. ;
Saab, S. ;
Ahmed, A. ;
Dieterich, D. ;
Gordon, S. C. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (06) :544-563
[46]   Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa [J].
Fraser, Ilanca ;
Burger, Johanita ;
Lubbe, Martie ;
Dranitsaris, George ;
Sonderup, Mark ;
Stander, Tienie .
PHARMACOECONOMICS, 2016, 34 (04) :403-417
[47]   Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C [J].
Rivero-Juarez, Antonio ;
Brieva, Teresa ;
Frias, Mario ;
Rivero, Antonio .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (09) :901-910
[48]   Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal [J].
Elbasha E.H. ;
Chhatwal J. ;
Ferrante S.A. ;
El Khoury A.C. ;
Laires P.A. .
Applied Health Economics and Health Policy, 2013, 11 (1) :65-78
[49]   ESTIMATING THE COST-EFFECTIVENESS OF 12 WEEKS OF TREATMENT WITH DACLATASVIR plus SOFOSBUVIR IN PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 3 [J].
McEwan, P. ;
Ward, T. ;
Webster, S. ;
Kalsekar, A. ;
Brenner, M. ;
Yuan, Y. .
VALUE IN HEALTH, 2015, 18 (03) :A240-A240
[50]   ESTIMATING THE COST-EFFECTIVENESS OF 12 WEEKS OF TREATMENT WITH DACLATASVIR plus SOFOSBUVIR IN PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 3 [J].
McEwan, P. ;
Ward, T. ;
Webster, S. ;
Kalsekar, A. ;
Brenner, M. ;
Yuan, Y. .
JOURNAL OF HEPATOLOGY, 2015, 62 :S666-S667
12345